We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
On this page, you will find the most up-to-date notices regarding current events and their impact on West Operations.
Hurricane Idalia - St. Petersburg, FL
Late Tuesday, August 29, Hurricane Idalia made landfall as a direct hit to the Southwest Florida region, impacting our St. Petersburg manufacturing site and our team members living there.
The hurricane has brought devastating wind, rain and subsequent flooding, with millions of people experiencing electricity outages.
Our main priority is the safety of our team members, and we are very thankful that our team members and their families remained safe through the storm.
Earlier in the week we activated our Business Continuity and Hurricane Preparedness Plans to ensure we took the appropriate measures to mitigate the risk to production at the site, enabling us to continue supplying critical components to our customers for the life-saving medicines they provide to patients around the world.
To support our team member’s safety, we closed our manufacturing site beginning second shift on Tuesday, August 29. We are pleased to report that our St. Pete site suffered minimal damage, with no flooding or electrical disruption.
Because of the commitment and hard work of our team there, we plan to reopen our site and return to full production starting with second shift on Wednesday, August 30. We will operate overtime throughout the next week to address the minimal downtime experienced. We do not anticipate any major impact to customer orders due to the hurricane.
Our thoughts continue to be with everyone in that region who were affected by this event.
We will continue to monitor the situation very closely and are committed to keeping our customers informed with any relevant updates.
Last Updated on August 30, 2023
Ukraine Situation
We are closely monitoring the situation in Ukraine and at this time, do not foresee any negative impact on West’s operations. West leverages its global supply chain and sources it’s raw materials from around the world to minimize risk and provide business continuity. We are committed to providing timely and transparent communications to all our stakeholders as we navigate through these evolving challenges and will provide an update if the situation changes.
Please download the customer letter by clicking the button below
Last Updated on December 9, 2022
Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
The need to provide vaccines for the SARS-CoV-2 pandemic has presented the pharmaceutical industry with unprecedented challenges. Among them are accelerated timelines for development/approval and unanticipated volumes for manufacture/delivery. Ordinarily for a new drug product, there is ample time for selecting the primary package system and establishing component availability.
Marisa Leuzzi, Senior Specialist, Global Communications, from our Exton Headquarters, is one of the growing number of coronavirus survivors. Her experiences with her illness is not uncommon – but what she did after her recovery to keep her family whole is remarkable.
Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
The need to provide vaccines for the SARS-CoV-2 pandemic has presented the pharmaceutical industry with unprecedented challenges. Among them are accelerated timelines for development/approval and unanticipated volumes for manufacture/delivery. Ordinarily for a new drug product, there is ample time for selecting the primary package system and establishing component availability.
Marisa Leuzzi, Senior Specialist, Global Communications, from our Exton Headquarters, is one of the growing number of coronavirus survivors. Her experiences with her illness is not uncommon – but what she did after her recovery to keep her family whole is remarkable.
English
Chinese
